Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHRQ To Compare Treatments For Women With Coronary Artery Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency for Healthcare Research and Quality seeks feedback on questions for a study of how women respond to various treatments, including medication and bypass surgery.

You may also be interested in...



AHRQ To Put More Than Half Of Stimulus CER Funding To Evidence Generation

The Agency for Healthcare Research and Quality is planning to spend $173 million, of the $300 million allocated to it for comparative effectiveness research by the American Recovery and Reinvestment Act, on evidence generation

CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously

Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.

French Firm Explores U.S. Regulatory Strategy For Blood-based Alzheimer’s Test

With a CE mark in hand, Exonhit is training its sights on the U.S. market. A 160-patient pilot study conducted through the Cleveland Clinic completed enrollment a few weeks ago.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel